In a study of BYETTA in subjects with end-stage renal disease receiving dialysis, mean exenatide exposure increased by 3.4-fold compared to that of subjects with normal renal function [see Warnings and Precautions (5.4) and Use in Specific Populations (8.6)]
Read More Safety Information/Precaution This product is intended for adult use only
Inadequate appetite suppression represents the most common reason people consider switching back or trying alternatives
Wang X, Anadn A, Wu Q, Qiao F, Ares I, Martnez-Larraaga MR, Yuan Z, Martnez MA (2018) Mechanism of neonicotinoid toxicity: impact on oxidative stress and metabolism
It begins at a dose of 0.25 mg/week in the first 4 weeks, then the subject raises the dose every 4 weeks up to a maintenance dose of 2.4 mg/week
It can also benefit those dealing with chronic conditions, as peptides can support the bodys healing and recovery processes